Atlas Trials

A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)

Clinical trial NCT04191304 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04191304
Sponsor
AstraZeneca
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Hypereosinophilic Syndrome
Start date
2020-07-20
Primary completion
2025-05-07
Enrollment
134

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.